newsengasertibepistaxis
Engasertib Shows Promise for Reducing Epistaxis in HHT but Benefits Are Modest — Safety Profile Acceptable in Short Term
By MedXY|Nov 27, 2025
A randomized, double-blind placebo-controlled proof-of-concept trial of engasertib (AKT inhibitor) in hereditary hemorrhagic telangiectasia showed modest reductions in epistaxis frequency and duration versus placebo and a tolerable safety p
